Investigation of the cause of autism using the medication Bumetanide

Phase 1

• Conditions: Autism Spectrum Disorder; Therapeutic area: Psychiatry and Psychology [F] - Mental Disorders [F03]

• Registration Number: EUCTR2021-003514-39-SE
• Lead Sponsor: Gillberg Neuropsychiatry Centre

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2021-08-11
• Last Update Posted: 8 October 2021

Recruitment & Eligibility

• Status: A
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

Autism Spectrum Disorder
Age 12-40 years old.
Are the trial subjects under 18? yes
Number of subjects for this age range: 25
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 25
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

Long QT syndrome
Intellectual disability

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified